Chardan Capital Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $8
Chardan Capital analyst Gautam Chukka initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $8.
Stocks · News reference
Tvardi Therapeutics Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In International Journal Of Molecular Sciences
In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
Tvardi Therapeutics, a clinical-stage biopharmaceutical company developing STAT3-targeting therapies, announced it will present at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The company is advancing TTI-109 for gastrointestinal diseases and TTI-101 in a Phase 1b/2 trial for hepatocellular carcinoma, with preclinical data supporting potential in ulcerative colitis treatment.
Tvardi Therapeutics shares are trading lower. The company announced the publication of preclinical ulcerative colitis data supporting its STAT3 inhibitor program.